Anovulation Differential Diagnoses

1. Warren MP, Vu C. Central causes of hypogonadism--functional and organic. Endocrinol Metab Clin North Am. 2003 Sep. 32(3):593-612. [QxMD MEDLINE Link].

2. Speroff L, Glass RH, Kase NG. Anovulation and the polycystic ovary syndrome. Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA: Lippincott Williams & Wilkins; 1999. 487-513.

3. Spence JE. Anovulation and monophasic cycles. Ann N Y Acad Sci. 1997 Jun 17. 816:173-6. [QxMD MEDLINE Link].

4. Yen SC, Jaffe RB, Barbieri RL. Chronic anovulation due to CNS-hypothalamic-pituitary dysfunction. Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. 4th ed. London, England: Elsevier Science; 1999.

5. Franks S, Mason H, White D, Willis D. Etiology of anovulation in polycystic ovary syndrome. Steroids. 1998 May-Jun. 63(5-6):306-7. [QxMD MEDLINE Link].

6. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv. 2002 Nov. 57(11):755-67. [QxMD MEDLINE Link].

7. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med. 1995 Jan 16. 98(1A):33S-39S. [QxMD MEDLINE Link].

8. Guzick DS, Hoeger K. Clinical Updates in Women's Health Care: Polycystic Ovary Syndrome. 2009 Jan.

9. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan. 81(1):19-25. [QxMD MEDLINE Link].

10. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. Endocr Pract. 2015 Nov. 21 (11):1291-300. [QxMD MEDLINE Link].

11. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb. 91(2):456-88. [QxMD MEDLINE Link].

12. [Guideline] Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug. 110 (3):364-79. [QxMD MEDLINE Link]. [Full Text].

13. Franks S, Robinson S, Willis DS. Nutrition, insulin and polycystic ovary syndrome. Rev Reprod. 1996 Jan. 1(1):47-53. [QxMD MEDLINE Link].

14. Pritts EA. Treatment of the infertile patient with polycystic ovarian syndrome. Obstet Gynecol Surv. 2002 Sep. 57(9):587-97. [QxMD MEDLINE Link].

15. Legro R. Polycystic ovary syndrome. Precis, Reproductive Endocrinology: An Update in Obstetrics and Gynecology. 2nd ed. American College of Obstetricians & Gynecologists; 2002. 85-89.

16. Thatcher S. Diagnosis of polycystic ovary syndrome. Female patient. 2004. 29:33-41.

17. Bloom MS, Perkins NJ, Sjaarda LA, et al. Adiposity is associated with anovulation independent of serum free testosterone: A prospective cohort study. Paediatr Perinat Epidemiol. 2021 Mar. 35 (2):174-83. [QxMD MEDLINE Link]. [Full Text].

18. Futterweit W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv. 1999 Jun. 54(6):403-13. [QxMD MEDLINE Link].

19. Bergfeld WF. Hirsutism in women. Effective therapy that is safe for long-term use. Postgrad Med. 2000 Jun. 107(7):93-4, 99-104. [QxMD MEDLINE Link].

20. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol. 1997 Apr. 24(4):223-9. [QxMD MEDLINE Link].

21. Schorge JO, Schaffer JI. Amenorrhea. Williams Gynecology. McGraw Hill; 2008.

22. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. 1974 Sep 13. 185(4155):949-51. [QxMD MEDLINE Link].

23. Andrico S, Gambera A, Specchia C, et al. Leptin in functional hypothalamic amenorrhoea. Hum Reprod. 2002 Aug. 17(8):2043-8. [QxMD MEDLINE Link].

24. Klein DA, Walsh BT. Eating disorders. Int Rev Psychiatry. 2003 Aug. 15(3):205-16. [QxMD MEDLINE Link].

25. Yen SC, Jaffe RB, Barbieri RL. Chronic anovulation caused by peripheral endocrine disorders. Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. 4th ed. London, England: Elsevier Science; 1999.

26. Warren MP, Perlroth NE. The effects of intense exercise on the female reproductive system. J Endocrinol. 2001 Jul. 170(1):3-11. [QxMD MEDLINE Link].

27. Mestman JH. Endocrine diseases in pregnancy. Gabbe S, Neibyl JR, eds. Obstetrics Normal and Problem Pregnancies. New York, NY: Churchill Livingstone; 2002. 4th ed: 1117-8.

28. Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N. Pituitary autoimmunity in patients with Sheehan's syndrome. J Clin Endocrinol Metab. 2002 Sep. 87(9):4137-41. [QxMD MEDLINE Link].

29. Velduis JD, Weiss J, Mauras N, et al. Appraising endocrine pulse signals at low circulating hormone concentrations: use of regional coefficients of variation in the experimental series to analyze pulsatile luteinizing hormone release. Pediatr Res. 1986 Jul. 20(7):632-7. [QxMD MEDLINE Link].

30. Bills DC, Meyer FB, Laws ER, et al. A retrospective analysis of pituitary apoplexy. Neurosurgery. 1993 Oct. 33(4):602-8; discussion 608-9. [QxMD MEDLINE Link].

31. Abe T, Ludecke DK. Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence. Surg Neurol. 2002 Jun. 57(6):369-78; discussion 378-9. [QxMD MEDLINE Link].

32. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am. 2001 Sep. 30(3):585-610. [QxMD MEDLINE Link].

33. Rasgon N. The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence. J Clin Psychopharmacol. 2004 Jun. 24(3):322-34. [QxMD MEDLINE Link].

34. Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol. 2008 Oct. 24(10):562-70. [QxMD MEDLINE Link].

35. Haiman CA, Pike MC, Bernstein L, et al. Ethnic differences in ovulatory function in nulliparous women. Br J Cancer. 2002 Feb 1. 86(3):367-71. [QxMD MEDLINE Link].

36. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ. 2011 Oct 13. 343:d6309. [QxMD MEDLINE Link]. [Full Text].

37. Goldman L, Ausiello D. Obesity. Cecil Textbook of Medicine. 22nd ed. 2004. 1346.

38. Wang R, Kim BV, van Wely M, Johnson NP, Costello MF, Zhang H, et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017 Jan 31. 356:j138. [QxMD MEDLINE Link].

39. Akande EO. Plasma concentration of gonadotrophins, oestrogen and progesterone in hypothyroid women. Br J Obstet Gynaecol. 1975 Jul. 82(7):552-6. [QxMD MEDLINE Link].

40. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun. 89(6):2745-9. [QxMD MEDLINE Link].

41. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol. 2003 Jun. 46(2):349-62. [QxMD MEDLINE Link].

42. Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol. 2003 Apr. 101(4):785-93. [QxMD MEDLINE Link].

43. Franks S, McCarthy M. Genetics of ovarian disorders: polycystic ovary syndrome. Rev Endocr Metab Disord. 2004 Mar. 5(1):69-76. [QxMD MEDLINE Link].

44. Hamilton-Fairley D, Taylor A. Anovulation. BMJ. 2003 Sep 6. 327(7414):546-9. [QxMD MEDLINE Link].

45. Malcolm CE, Cumming DC. Does anovulation exist in eumenorrheic women?. Obstet Gynecol. 2003 Aug. 102(2):317-8. [QxMD MEDLINE Link].

46. Norman RJ, Wu R, Stankiewicz MT. 4: Polycystic ovary syndrome. Med J Aust. 2004 Feb 2. 180(3):132-7. [QxMD MEDLINE Link].

47. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2003 Jun. 30(2):337-52. [QxMD MEDLINE Link].

48. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003 Sep 16. 169(6):575-81. [QxMD MEDLINE Link].

49. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004 Jan. 60(1):1-17. [QxMD MEDLINE Link].

50. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. Fertil Steril. 2008 Nov. 90(5 Suppl):S7-12. [QxMD MEDLINE Link].

51. Warren MP, Brooks-Gunn J, Fox RP, et al. Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study. Fertil Steril. 2003 Aug. 80(2):398-404. [QxMD MEDLINE Link].

52. Warren MP, Goodman LR. Exercise-induced endocrine pathologies. J Endocrinol Invest. 2003 Sep. 26(9):873-8. [QxMD MEDLINE Link].

53. Prior JC, Naess M, Langhammer A, Forsmo S. Ovulation prevalence in women with spontaneous normal-length menstrual cycles - a population-based cohort from HUNT3, Norway. PLoS One. 2015. 10(8):e0134473. [QxMD MEDLINE Link].

54. Schliep KC, Zarek SM, Schisterman EF, et al. Alcohol intake, reproductive hormones, and menstrual cycle function: a prospective cohort study. Am J Clin Nutr. 2015 Oct. 102(4):933-42. [QxMD MEDLINE Link].

55. Palihawadana TS, Wijesinghe PS, Seneviratne HR. Factors associated with nonresponse to ovulation induction using letrozole among women with World Health Organization group II anovulation. J Hum Reprod Sci. 2015 Apr-Jun. 8(2):75-9. [QxMD MEDLINE Link].

Armando E Hernandez-Rey, MD Consulting Staff, Reproductive Endocrinology and Infertility, Robotic and Minimally Invasive Surgery, Conceptions: Center for Fertility & Genetics of Florida; Assistant Professor of Women's Health, Florida International University College of Medicine

Armando E Hernandez-Rey, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, American Society for Reproductive Medicine, Society for Reproductive Investigation, Society of Laparoscopic and Robotic Surgeons, AAGL, Society for Reproductive Endocrinology and Infertility

Disclosure: Received consulting fee from Inuitive Surgical for independent contractor; Received consulting fee from Vita Med MD for speaking and teaching.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Frances E Casey, MD, MPH Associate Professor, Director of Family Planning Services, Department of Obstetrics and Gynecology, VCU Medical Center

Frances E Casey, MD, MPH is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Reproductive Health Professionals, National Abortion Federation, Physicians for Reproductive Health, Society of Family Planning

Disclosure: Nothing to disclose.

Richard Scott Lucidi, MD, FACOG Associate Professor of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine

Richard Scott Lucidi, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous authors Krystene I Boyle, MD, Cassandra Blot, MD, and Peter G McGovern, MD, to the development and writing of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article